Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples